References
- American Academy of Pain Medicine. Available from www.painmed.org/patientcenter/facts_on_pain.aspx. Accessed 6 November 2014.
- Dagenais S, Tricco AC, Haldeman S. Synthesis of recommendations for the assessment and management of low back pain from recent clinical practice guidelines. Spine J 2010;10:514–29.
- Section IV. Management of Acute Pain and Chronic Noncancer Pain from the American Society for Pain. Available from www.americanpainsociety.org/uploads/pdfs/npc/section_4.pdf. Accessed 6 November 2014.
- Chou R. 2009 Clinical Guidelines from the American Pain Society and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic noncancer pain: what are the key messages for clinical practice? Pol Arch Med Wewn 2009;119:469–77.
- Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007;147:478–91.
- Drug Enforcement Administration. US Department of Justice. Drug Fact Sheet: Hydrocodone. Available from www.justice.gov/dea/druginfo/drug_data_sheets/Hydrocodone.pdf. Accessed 6 November 2014.
- Von Korff M, Saunders K, Thomas Ray G, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain 2008;24:521–7.
- Vicodin (hydrocodone bitartrate and acetaminophen tablets) [package insert]. North Chicago, IL: AbbVie Inc.; 2014. Available from http://www.rxabbvie.com/pdf/vicodin_apap_300mg_hydrocodone_5mg-7.5mg-10mg_PI.pdf. Accessed 25 November 2014.
- Food and Drug Administration: Acetaminophen Overdose and Liver Injury — Background and Options for Reducing Injury. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM164897.pdf. Accessed 6 November 2014.
- Substance Abuse and Mental Health Services Administration Data. Available from: www.samhsa.gov/data. Accessed 17 September 2014.
- Wen WS, Lynch S, He E, Ripa SR. Efficacy and safety of once-daily hydrocodone (HysinglaTM ER) in CLBP. Presented at PAINWeek; 2014. Abstract 146. Available from http://conference.painweek.org/media/mediafile_attachments/04/734-pgmpainjournalbw.pdf.
- Lynch SW, Taber L, Munera C, Ripa S. Long-term safety and effectiveness of once-daily, single-entity, abuse-deterrent hydrocodone in chronic nonmalignant and nonneuropathic pain: results of a long-term open-label study. J Pain 2014;15:S91.
- Foley KM. The treatment of cancer pain. N Engl J Med 1985;313:84–95.
- American Pain Society. Principles of analgesic use in the treatment of acute pain and cancer pain (Sixth edition). Glenview, IL: APS Press; 2003. p 19–21.
- Management of Opioid Therapy for Chronic Pain Working Group. VA/DoD clinical practical guidelines for the management of opioid therapy for chronic pain. Contract Number V101(93)P-1633(version 2.0). 2010; Appendix E: Table E 6.
- Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996;64:527–34.
- Werneke MW, Hart DL. Categorizing patients with occupational low back pain by use of the Quebec Task Force Classification system versus pain pattern classification procedures: discriminant and predictive validity. Phys Ther 2004;84:243–54.
- Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician 2008;11:S105–20.
- Rauck RL, Nalamachu S, Wild JE, et al. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study. Pain Med 2014;15:975–85.
- Sauro MD, Greenberg RP. Endogenous opiates and the placebo effect: a meta-analysis review. J Psychosom Res 2005;58:115–20.